Concepedia

Author

Jeffrey C. Jerman

GlaxoSmithKline (United Kingdom)

Also Known As

J C Jerman, J C. Jerman, J. C. JERMAN, J. C. Jerman, J. JERMAN, J. Jerman, J.C Jerman, J.C. Jerman, Jeffrey C Jerman, Jeffrey C. Jerman

54

Publications

4.7K

Citations

28

H-Index

45

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)Molecular Discovery (United Kingdom)New FrontierLifeArcQueen's Medical Centre
JC

About

Jeffrey C. Jerman is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

22

3K

2

Natural Sciences

8

8

1.6K

3

Health Sciences

2

2

510

4

Social Sciences

2

2

162

5

Anesthesia

1

1

98

Jeffrey C. Jerman

×

33

Publications

4.5K

Citations

26

H-Index

YearCitations

TRPV3 is a temperature-sensitive vanilloid receptor-like protein

George Davey Smith, Martin J. Gunthorpe, Rosemary E. Kelsell,

Nature

2002

833

The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)

D Smart, Martin J. Gunthorpe, Jeffrey C. Jerman,

British Journal of Pharmacology

2000

769

Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1

Marcello Trevisani, D Smart, Martin J. Gunthorpe,

Nature Neuroscience

2002

445

SB‐334867‐A: the first selective orexin‐1 receptor antagonist

D Smart, Cibele Sabido-David, Stephen Brough,

British Journal of Pharmacology

2001

312

Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist

Martin J. Gunthorpe, Harshad K. Rami, Jeffrey C. Jerman,

Neuropharmacology

2003

272

Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell‐line using FLIPR

D Smart, Jeffrey C. Jerman, Stephen Brough,

British Journal of Pharmacology

1999

187

1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor

Roderick A. Porter, Wai N. Chan, Steven Coulton,

Bioorganic & Medicinal Chemistry Letters

2001

165

Characterisation of the binding of [<sup>3</sup>H]‐SB‐674042, a novel nonpeptide antagonist, to the human orexin‐1 receptor

Christopher J. Langmead, Jeffrey C. Jerman, Stephen Brough,

British Journal of Pharmacology

2004

136

Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development

Harshad K. Rami, Mervyn Thompson, Geoffrey Stemp,

Bioorganic & Medicinal Chemistry Letters

2006

132

Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacology

Jeffrey C. Jerman, Stephen Brough, Rab K. Prinjha,

British Journal of Pharmacology

2000

116

Page 1